CO7131365A2 - Factores de coagulación de acción prolongada y métodos de producción de los mismos - Google Patents

Factores de coagulación de acción prolongada y métodos de producción de los mismos

Info

Publication number
CO7131365A2
CO7131365A2 CO14178314A CO14178314A CO7131365A2 CO 7131365 A2 CO7131365 A2 CO 7131365A2 CO 14178314 A CO14178314 A CO 14178314A CO 14178314 A CO14178314 A CO 14178314A CO 7131365 A2 CO7131365 A2 CO 7131365A2
Authority
CO
Colombia
Prior art keywords
long
production methods
coagulation factors
acting coagulation
acting
Prior art date
Application number
CO14178314A
Other languages
English (en)
Inventor
Udi Eyal Fima
Gili Hart
Original Assignee
Prolor Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48983616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7131365(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/372,540 external-priority patent/US8759292B2/en
Application filed by Prolor Biotech Inc filed Critical Prolor Biotech Inc
Publication of CO7131365A2 publication Critical patent/CO7131365A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Glass Compositions (AREA)

Abstract

Se describen polipéptidos que comprenden al menosun péptido de extremo carboxi (CTP) de gonadotropina 5 coriónica unida al extremo carboxi pero no al extremo amino de un factor de coagulación y polinucleótidos que codifican los mismos. También se describen composiciones farmacéuticas que comprenden los polipéptidos y polinucleótidos de la invención y métodos de utilización y producción de los 10 mismos.
CO14178314A 2012-02-14 2014-08-14 Factores de coagulación de acción prolongada y métodos de producción de los mismos CO7131365A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/372,540 US8759292B2 (en) 2006-02-03 2012-02-14 Long-acting coagulation factors and methods of producing same

Publications (1)

Publication Number Publication Date
CO7131365A2 true CO7131365A2 (es) 2014-12-01

Family

ID=48983616

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14178314A CO7131365A2 (es) 2012-02-14 2014-08-14 Factores de coagulación de acción prolongada y métodos de producción de los mismos

Country Status (22)

Country Link
EP (3) EP3326642B1 (es)
JP (2) JP6242819B2 (es)
KR (3) KR102310704B1 (es)
CN (2) CN104427994A (es)
AU (3) AU2013219935B2 (es)
BR (1) BR122021004014B1 (es)
CA (1) CA2870621C (es)
CL (2) CL2014002183A1 (es)
CO (1) CO7131365A2 (es)
DK (2) DK3326642T3 (es)
EA (2) EA028578B1 (es)
ES (2) ES2665319T3 (es)
HK (1) HK1205460A1 (es)
HU (1) HUE053068T2 (es)
IL (2) IL264959B (es)
MX (3) MX362446B (es)
MY (1) MY172539A (es)
NO (1) NO2920022T3 (es)
PE (1) PE20142290A1 (es)
PL (1) PL3326642T3 (es)
SG (1) SG11201404836QA (es)
WO (1) WO2013121416A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
JP6242819B2 (ja) 2012-02-14 2017-12-06 オプコ バイオロジクス リミテッド 長時間作用型凝固因子およびその生成方法
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
SG11201704706RA (en) 2014-12-10 2017-07-28 Opko Biologics Ltd Methods of producing long acting ctp-modified growth hormone polypeptides
WO2016203482A2 (en) * 2015-06-19 2016-12-22 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
BR112019000610A2 (pt) * 2016-07-11 2019-07-02 Opko Biologics Ltd fator vii de coagulação de longa ação e métodos de produção do mesmo
EP3502143A4 (en) 2016-08-19 2020-07-15 Ampsource Biopharma Shanghai Inc. BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759694B (zh) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
JP7023925B2 (ja) 2017-03-08 2022-02-22 テイ・エス テック株式会社 乗物用シート
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
DE3421468A1 (de) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
CA2053864C (en) 1989-02-21 2001-11-20 Irving Boime Modified forms of reproductive hormones
US6225449B1 (en) 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
US5792460A (en) * 1989-02-21 1998-08-11 Washington University Modified glycoprotein hormones having a CTP at the amino terminus
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
US7795210B2 (en) * 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
CN1245510C (zh) * 2003-09-25 2006-03-15 复旦大学 长效重组组织因子途径抑制物及其制备方法
US7553940B2 (en) 2006-02-03 2009-06-30 Modigene Inc Long-acting EPO polypeptides and derivatives thereof and methods thereof
US8759292B2 (en) * 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US8048849B2 (en) * 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
TWI538916B (zh) * 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
KR20110039348A (ko) * 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
JP6242819B2 (ja) 2012-02-14 2017-12-06 オプコ バイオロジクス リミテッド 長時間作用型凝固因子およびその生成方法
ES2882890T3 (es) * 2012-11-20 2021-12-03 Opko Biologics Ltd Método para aumentar el volumen hidrodinámico de polipéptidos mediante la unión a péptidos carboxi terminales de la gonadotrofina

Also Published As

Publication number Publication date
ES2665319T3 (es) 2018-04-25
KR20210125595A (ko) 2021-10-18
BR112014020198A2 (pt) 2018-05-15
EP2822576A4 (en) 2015-11-25
MX2014009910A (es) 2015-09-28
JP6510002B2 (ja) 2019-05-08
EA201491519A1 (ru) 2014-12-30
CA2870621A1 (en) 2013-08-22
HK1205460A1 (en) 2015-12-18
EA028578B1 (ru) 2017-12-29
EA201790960A3 (ru) 2018-01-31
AU2016202829A1 (en) 2016-05-19
EP2822576A1 (en) 2015-01-14
EP3791890A1 (en) 2021-03-17
JP2018065815A (ja) 2018-04-26
MX362446B (es) 2019-01-18
CN109535245A (zh) 2019-03-29
DK3326642T3 (da) 2021-02-22
MX2019000708A (es) 2020-09-02
WO2013121416A1 (en) 2013-08-22
KR20140134673A (ko) 2014-11-24
SG11201404836QA (en) 2014-12-30
KR20200063274A (ko) 2020-06-04
MY172539A (en) 2019-11-30
AU2013219935B2 (en) 2016-02-04
CA2870621C (en) 2022-08-09
HUE053068T2 (hu) 2021-06-28
IL282121B (en) 2022-06-01
AU2017219044A1 (en) 2017-09-14
AU2013219935A1 (en) 2014-09-25
EP3326642A1 (en) 2018-05-30
PE20142290A1 (es) 2015-01-15
AU2016202829B2 (en) 2017-05-25
EA201790960A2 (ru) 2017-09-29
KR102310704B1 (ko) 2021-10-08
BR122021004014B1 (pt) 2022-12-27
CL2017002233A1 (es) 2018-05-11
DK2822576T3 (en) 2018-04-16
KR102118729B1 (ko) 2020-06-05
CL2014002183A1 (es) 2015-01-09
IL264959B (en) 2021-08-31
EP3326642B1 (en) 2020-11-25
CN104427994A (zh) 2015-03-18
IL282121A (en) 2021-05-31
EP2822576B1 (en) 2018-01-10
NO2920022T3 (es) 2018-06-09
KR102630953B1 (ko) 2024-01-29
PL3326642T3 (pl) 2021-06-14
ES2855133T3 (es) 2021-09-23
JP2015508771A (ja) 2015-03-23
AU2017219044B2 (en) 2019-05-30
JP6242819B2 (ja) 2017-12-06
MX2022008807A (es) 2022-08-11

Similar Documents

Publication Publication Date Title
CO7131365A2 (es) Factores de coagulación de acción prolongada y métodos de producción de los mismos
CY1118733T1 (el) Παραγοντες πηξης μακρας διαρκειας και μεθοδοι παραγωγης των ιδιων
AU2019201173B2 (en) Novel polypeptides
CU20190058A7 (es) Composiciones de aminoácidos relacionadas con mejoras de la función hepática
CY1121891T1 (el) Τροποποιημενα με γενετικη μηχανικη πολυπεπτιδια της λυασης φαινυλαλανινης-αμμωνιας
BR112014000466A2 (pt) polipeptídeos quiméricos e híbridos fator viii, métodos de uso dos mesmos
CY1124682T1 (el) Ανταγωνιστες toy trpv4
IN2015DN00003A (es)
WO2016203482A3 (en) Long-acting coagulation factors and methods of producing same
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
UA118167C2 (uk) Пептид та його застосування
EA201792245A1 (ru) Биоконъюгаты и их применения
UY34730A (es) Formulaciones farmacéuticas que comprenden antagonistas de ccr3
EP3450449A3 (en) Peptide compositions
BR112016015701A2 (pt) Dendrímero de peptídeo, método de esterilização do mesmo, composição, composição farmacêutica, método de polimerização de fibrinogênio, kit para formação de um hidrogel e hidrogel
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
WO2015022575A3 (en) A process for the preparation of gc-c agonist
WO2015198240A3 (en) Compositions and methods for long acting proteins
CL2017003144A1 (es) Péptidos lipidados resistentes a proteasas
BR112016019390A2 (pt) proteínas de fusão uti
BR112012030084A2 (pt) peptídeos que se ligam a receptores do fator de crescimento semelhante à insulina tipo 1
NZ744289A (en) Composition containing amino acids
SG10201803999UA (en) Recombinant factor viii formulations
EP2899198A4 (en) SYNTHETIC PNTX (19) -EPEPTIDES, PHARMACEUTICAL COMPOSITIONS AND USES
BR112016007031A8 (pt) composição farmacêutica oral sólida, processo para preparar a composição farmacêutica oral sólida, e uso de uma composição farcêutica oral sólida